BEIJING, Aug 18 (Reuters): China's vaccine specialist CanSino Biologics Inc has won a patent approval from Beijing for its Covid-19 vaccine candidate Ad5-nCOV, state media reported, citing documents from the country's intellectual property regulator.
It is the first Covid-19 vaccine patent granted by China, state-owned newspaper People's Daily reported on Sunday (Aug 16).
Already a subscriber? Log in.
Get 30% off with our ads free Premium Plan!
Cancel anytime. No ads. Auto-renewal. Unlimited access to the web and app. Personalised features. Members rewards.
Follow us on our official WhatsApp channel for breaking news alerts and key updates!